Home
Stocks
Firebrick Pharma Limited
Filings
Firebrick Pharma Limited (ASX:FRE) Filings
Firebrick Pharma Limited
Filings
Filing
Date
Type
Filed with
Notification regarding unquoted securities - FRE
Nov 16, 2026
Other filings
ASX
Change of Director's Interest Notice - Stephen Goodall
Nov 16, 2026
Ownership change notice
ASX
Change of Director's Interest Notice - Rick Legleiter
Nov 16, 2026
Ownership change notice
ASX
Change of Director's Interest Notice - Peter Molloy
Nov 16, 2026
Ownership change notice
ASX
Change of Director's Interest Notice - Al Moghaddam
Nov 16, 2026
Ownership change notice
ASX
Proposed issue of securities - FRE
Nov 11, 2026
Financing
ASX
Results of Annual General Meeting
Nov 10, 2026
Meeting outcome
ASX
September 2026 Quarterly Activity Report & Appendix 4C
Oct 22, 2026
Quarterly report
ASX
New Product - Nasodine Sinus Rinse
Oct 20, 2026
Operations update
ASX
New Product - Nasodine Sinus Rinse
Oct 20, 2026
Operations update
ASX
Change in substantial holding - Pharma Nutria
Oct 19, 2026
Ownership change notice
ASX
Cleansing Notice
Oct 18, 2026
Financing
ASX
Application for quotation of securities - FRE
Oct 18, 2026
Financing
ASX
Nasodine Nasal Spray Approved in the Philippines
Oct 15, 2026
Operations update
ASX
Notice of AGM & Proxy Form & Letter to Shareholders
Oct 11, 2026
Meeting notice
ASX
Proposed issue of securities - FRE
Oct 11, 2026
Financing
ASX
Firebrick Secures $732k in Strategic Investments
Oct 11, 2026
Financing
ASX
Firebrick Investor Update Presentation
Oct 6, 2026
Operations update
ASX
Firebrick announces USA Retail Launch Plan
Sep 28, 2026
Operations update
ASX
Firebrick receives $293,000 R&D Tax Incentive
Sep 22, 2026
Results
ASX
Notice of AGM and Closing Date for Director Nominations
Sep 14, 2026
Meeting notice
ASX
Appendix 4E and Annual Report 30 June 2026
Aug 31, 2026
Annual report
ASX
Appendix 4G
Aug 31, 2026
Other filings
ASX
Corporate Governance Statement
Aug 31, 2026
Other filings
ASX
Cleansing Notice
Aug 10, 2026
Notification letter
ASX
Application for quotation of securities - FRE
Aug 10, 2026
Financing
ASX
Proposed issue of securities - FRE
Aug 9, 2026
Financing
ASX
Investor Update
Jul 26, 2026
Operations update
ASX
March 2026 Quarterly Activity Report & Appendix 4C
Apr 21, 2026
Quarterly report
ASX
Firebrick Secures $1.5 million via Placement
Mar 30, 2026
Financing
ASX
Trading Halt
Mar 26, 2026
Trading halt or suspension
ASX
Registration Agreement and Approval of Nasodine in Indonesia
Mar 26, 2026
Operations update
ASX
Appendix 4D & Half-Year Financial Report to 31 December 2025
Feb 24, 2026
Interim report
ASX
December 2025 Quarterly Activity Report & Appendix 4C
Jan 27, 2026
Quarterly report
ASX
Nasodine Throat Spray Product Launch in Singapore
Jan 20, 2026
Operations update
ASX
Firebrick announces new product Nasodine Throat Spray
Oct 29, 2025
Operations update
ASX
September 2025 Quarterly Activity Report & Appendix 4C
Oct 22, 2025
Quarterly report
ASX
Firebrick Secures Investment from Philippines Partner
Oct 15, 2025
Financing
ASX
Firebrick receives $250,000 R&D Tax Incentive
Sep 9, 2025
Financing
ASX
Appendix 4E and Annual Report 30 June 2025
Aug 29, 2025
Annual report
ASX
Firebrick Secures $1.4 million via Placement
Aug 25, 2025
Financing
ASX
License Agreement for Singapore, Malaysia, Brunei, Mauritius
Aug 25, 2025
Material contract
ASX
June 2025 Quarterly Activity Report & Appendix 4C
Jul 22, 2025
Quarterly report
ASX
Firebrick Closes Placement at $0.2 milliion
Jun 25, 2025
Financing
ASX
Withdrawal of Share Placement
Jun 6, 2025
Financing
ASX
March 2025 Quarterly Activity Report & Appendix 4C
Apr 16, 2025
Quarterly report
ASX
FRE secures Strategic Investment from Philippines Partner
Mar 3, 2025
Other filings
ASX
Appendix 4D & Half-Year Financial Report to 31 December 2024
Feb 20, 2025
Interim report
ASX
December 2024 Quarterly Activity Report & Appendix 4C
Jan 22, 2025
Quarterly report
ASX
Nasodine Retail Pharmacy Launch in Singapore
Nov 24, 2024
Other filings
ASX
Agreement Signed to Market Nasodine to HCPs in Singapore
Oct 30, 2024
Other filings
ASX
September 2024 Quarterly Activity Report & Appendix 4C
Oct 22, 2024
Quarterly report
ASX
Completion of Share Purchase Plan
Oct 9, 2024
Financing
ASX
Firebrick receives $0.9 million R&D Tax Incentive
Sep 22, 2024
Other filings
ASX
Share Purchase Plan
Sep 11, 2024
Financing
ASX
Appendix 4E and Annual Report 30 June 2024
Aug 30, 2024
Annual report
ASX
New agreement allows Nasodine launch in Philippines
Aug 14, 2024
Operations update
ASX
June 2024 Quarterly Activity Report & Appendix 4C
Jul 29, 2024
Quarterly report
ASX
Firebrick Launches Nasodine in Singapore
Jun 12, 2024
Operations update
ASX
Firebrick Raises $800,000 via Placement
May 16, 2024
Financing
ASX
March 2024 Quarterly Activity Report & Appendix 4C
Apr 22, 2024
Quarterly report
ASX
Nasodine Nasal Spray Launch in the USA
Apr 16, 2024
Operations update
ASX
Appendix 4D & Half-Year Financial Report to 31 December 2023
Feb 28, 2024
Interim report
ASX
December 2023 Quarterly Activity Report & Appendix 4C
Jan 23, 2024
Quarterly report
ASX
Firebrick Investor Update
Nov 14, 2023
Operations update
ASX
Firebrick Receives $1.81m R&D Tax Incentive
Oct 30, 2023
Financing
ASX
September 2023 Quarterly Activity Report & Appendix 4C
Oct 26, 2023
Quarterly report
ASX
Update on Nasodine Trial and Forward Plans
Oct 2, 2023
Operations update
ASX
Phase 3 Common Cold Trial Results
Sep 13, 2023
Other filings
ASX
Appendix 4E & Annual Report FY23
Aug 29, 2023
Annual report
ASX
Response to ASX Price and Volume Query
Aug 28, 2023
Explanation request
ASX
Firebrick Phase 3 Trial Closes with 500 Subjects
Aug 8, 2023
Other filings
ASX
Firebrick Covid-19 Trial Achieves Primary Endpoint
Aug 6, 2023
Other filings
ASX
June 2023 Quarterly Activity Report & Appendix 4C
Jul 26, 2023
Quarterly report
ASX
Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
May 30, 2023
Other filings
ASX
Firebrick Raises $1 million via Placement
Apr 30, 2023
Financing
ASX
March 2023 Quarterly Activity Report & Appendix 4C
Apr 19, 2023
Quarterly report
ASX
Nasodine COVID-19 Trial Concludes Recruitment
Apr 3, 2023
Other filings
ASX
Firebrick Pharmas Phase 3 Trial of Nasodine Resumes
Mar 20, 2023
Other filings
ASX
FRE files EU Paediatric Investigation Plan for Nasodine
Feb 20, 2023
Legal or regulatory action
ASX
Appendix 4D & Half Yearly Report and Accounts
Feb 17, 2023
Interim report
ASX
December 2022 Quarterly Activity Report & Appendix 4C
Jan 18, 2023
Quarterly report
ASX
Nasodine Composition Patent Accepted in Australia
Nov 13, 2022
Other filings
ASX
Firebrick Receives $1.08m R&D Tax Incentive
Nov 8, 2022
Other filings
ASX
September 2022 Quarterly Activity Report & Appendix 4C
Oct 31, 2022
Quarterly report
ASX
Appendix 4E & Annual Report
Aug 23, 2022
Annual report
ASX
June 2022 Quarterly Activity Report & Appendix 4C
Jul 28, 2022
Quarterly report
ASX
Outcome of s60 appeal for Nasodine and next steps
Jul 7, 2022
Other filings
ASX
Firebrick starts Phase 3 common cold trial of Nasodine
May 3, 2022
Other filings
ASX
March 2022 Quarterly Activity Report & Appendix 4C
Apr 26, 2022
Quarterly report
ASX
Firebrick starts COVID-19 trial of Nasodine
Apr 26, 2022
Other filings
ASX
31 December Interim Financial Report & Appendix 4D
Feb 11, 2022
Interim report
ASX